Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?

Bibliography

• Zimm S, Wampler GL, Stablein D, Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 1981;20:384-94
   Web of Science ®Google Scholar
• Cappuzzo F, Mazzoni F, Maestri Di Stefano A, Medical treatment of brain metastases from solid tumours. Forum (Genova) 2000;10:137-49
   PubMedGoogle Scholar
• Brady LW, Mancall EL, Lee DK, Radiation therapy for intracranial metastatic neoplasia. Radiol Clin Biol 1974;43:40-7
   PubMedGoogle Scholar
• DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989;39:789-96
   PubMed Web of Science ®Google Scholar
• Murray KJ, Scott C, Greenberg HM, A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 1997;39:571-4
   PubMed Web of Science ®Google Scholar
• Kocher M, Soffietti R, Abacioglu U, Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011;29(3):279-86
   PubMedGoogle Scholar
• Paumier A, Le Pechoux C. Radiotherapy in small-cell lung cancer: where should it go? Lung Cancer 2010;69(2):133-40
   PubMed Web of Science ®Google Scholar
• Le Pechoux C, Dunant A, Senan S, Prophylactic Cranial Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01: a randomised clinical trial. Lancet Oncol 2009;10(5):467-74
   PubMed Web of Science ®Google Scholar
• Sun A, Bae K, Gore EM, Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol 2011;29(3):279-86
   PubMed Web of Science ®Google Scholar
• Gaspar LE, Scott C, Rotman M, Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-51
   PubMed Web of Science ®Google Scholar
• Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005;23(25):6207-19
   PubMed Web of Science ®Google Scholar
• Bernardo G, Cuzzoni Q, Strada MR, First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest 2002;20:293-302
   PubMed Web of Science ®Google Scholar
• Robinet G, Thomas P, Breton JL, Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95–1. Ann Oncol 2001;12:59-67
   PubMed Web of Science ®Google Scholar
• Boogerd W, Dalesio O, Bais EM, Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992;69:972-80
   PubMed Web of Science ®Google Scholar
• Quantin X, Khial F, Reme-Saumon M, Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer. Lung Cancer 1999;26:35-9
   PubMed Web of Science ®Google Scholar
• van den Bent MJ. The role of chemotherapy in brain metastases. Eur J Cancer 2003;39(15):2114-20
   PubMed Web of Science ®Google Scholar
• Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12(7):884-98
   PubMed Web of Science ®Google Scholar
• Stevens MFG, Hickman JA, Langdon SP, Antitumor activity and pharmacokinetics in mice of 8-carbomoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin- 4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative dacarbazine. Cancer Res 1987;47:5846-52
   PubMed Web of Science ®Google Scholar
• Newlands ES, Blackledge GR, Slack JA, Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65:287-91
   PubMed Web of Science ®Google Scholar
• Tsang LL, Farmer PB, Gescher A, Slack JA. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol 1990;26:429-36
   PubMed Web of Science ®Google Scholar
• Patel M, McCully C, Godwin, Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Am Soc Clin Oncol 1995;14:1485a
   Google Scholar
• Newlands ES, Stevens MFG, Wedge SR, Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61
   PubMed Web of Science ®Google Scholar
• Margison G, Koref MS, Povey A. Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis 2002;17:483-7
   PubMed Web of Science ®Google Scholar
• Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL and Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994;33:9045-51
   PubMed Web of Science ®Google Scholar
• Roos WP, Batista LF, Naumann SC, Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O(6)-methylguanine. Oncogene 2007;26:186-97
   PubMed Web of Science ®Google Scholar
• Wu PF, Kuo KT, Kuo LT, O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer 2010;68(3):484-90
   PubMed Web of Science ®Google Scholar
• O'Reilly SM, Newlands ES, Glaser MG, Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993;29A(7):940-2
   PubMed Web of Science ®Google Scholar
• Brada M, Judson I, Beale P, Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999;81:1022-30
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, On behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group (NCIC CTG): Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med 2005;352:987-96
   PubMed Web of Science ®Google Scholar
• Bleehen NM, Newlands ES, Lee SM, Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13(4):910-13
   PubMed Web of Science ®Google Scholar
• Bower M, Newlands ES, Bleehen NM, Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997;40(6):484-8
   PubMed Web of Science ®Google Scholar
• Abrey LE, Olson JD, Raizer JJ, A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001;53(3):259-65
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Bafaloukos D, Kosmidis P, Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001;12(2):249-54
   PubMed Web of Science ®Google Scholar
• Abrey LE, Christodoulou C. Temozolomide for treating brain metastases. Semin Oncol 2001;28(4 Suppl 13):34-42
   PubMed Web of Science ®Google Scholar
• Bleehen NM, Newlands ES, Lee SM, Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13:910-13
   PubMed Web of Science ®Google Scholar
• Paul MJ, Summers Y, Calvert AH, Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002;12(2):175-8
   PubMed Web of Science ®Google Scholar
• Schild SE, Behl D, Markovic SN, Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? Am J Clin Oncol 2010;33(6):633-6
   PubMed Web of Science ®Google Scholar
• Trudeau ME, Crump M, Charpentier D, Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 2006;17(6):952-6
   PubMed Web of Science ®Google Scholar
• Antonadou D, Paraskevaidis M, Sarris M, Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002;20:3644-50
   PubMed Web of Science ®Google Scholar
• Verger E, Gil M, Yaya R, Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005;61:185-91
   PubMed Web of Science ®Google Scholar
• Wedge SR, Porteous JK, Glaser MG, In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 1997;8(1):92-7
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Faiola V, Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer 2007;7:18
   PubMed Web of Science ®Google Scholar
• Kouvaris JR, Miliadou A, Kouloulias VE, Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie 2007;30(7):361-6
   PubMed Web of Science ®Google Scholar
• Mikkelsen T, Anderson J, Doyle TJ, Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis. J Neurooncol 2010;7:241-7
   Google Scholar
• Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005;23(25):6207-19
   PubMed Web of Science ®Google Scholar
• Chua D, Krzakowski M, Chouaid C, Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. Clin Lung Cancer 2010;11(3):176-81
   PubMed Web of Science ®Google Scholar
• Addeo R, De Rosa C, Faiola V, Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for non small cell lung cancer and breast cancer patients with brain metastases. Cancer 2008;113(9):2524-31
   PubMed Web of Science ®Google Scholar
• Tentori L, Leonetti C, Scarsella M, Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 2006;20(10):1709-11
   PubMed Web of Science ®Google Scholar
• Schwarzberg AB, Stover EH, Sengupta T, Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest 2007;25(4):249-55
   PubMed Web of Science ®Google Scholar
• Cortot AB, Geriniere L, Robinet G, Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol 2006;17(9):1412-17
   PubMed Web of Science ®Google Scholar
• Omuro AM, Raizer JJ, Demopoulos A, Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. J Neurooncol 2006;78(3):277-80
   PubMed Web of Science ®Google Scholar
• Iwamoto FM, Omuro AM, Raizer JJ, A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2008;87(1):85-90
   PubMed Web of Science ®Google Scholar
• Bafaloukos D, Gogas H, Georgoulias V, Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002;20(2):420-5
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JHP. Reclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 1998;9(1):1-17
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Choy H, Kearns CM, Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 1995;87(14):1077-81
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 1996;7(1):78-86
   PubMed Web of Science ®Google Scholar
• Rivera E, Meyers C, Groves M, Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast cancer. Cancer 2006;107:1348-54
   PubMed Web of Science ®Google Scholar
• Larkin JM, Hughes SA, Beirne DA, A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer 2007;96(1):44-8
   PubMed Web of Science ®Google Scholar
• Ebert BL, Niemierko E, Shaffer K, Salgia R. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist 2003;8(1):69-75
   PubMed Web of Science ®Google Scholar
• Kienast Y, Winkler F. Therapy and prophylaxis of brain metastases. Expert Rev Anticancer Ther 2010;10(11):1763-77
   PubMed Web of Science ®Google Scholar
• Mehta MP, Paleologos NA, Mikkelsen T, The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96(1):71-83
   PubMed Web of Science ®Google Scholar
• Ammirati M, Cobbs CS, Linskey ME, The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96(1):85-96
   PubMed Web of Science ®Google Scholar
• Caraglia M, Marra M, Budillon A. Highlights of the Annual Meeting of the Italian Association for Cell Cultures (AICC): new drug delivery strategies and technological platforms for diagnosis and therapy of tumors. Part II. 6 – 7 December 2007, Naples, Italy. Expert Opin Biol Ther 2008;8(7):1031-5
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Koukouraki S, Fezoulidis I, High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 2000;83(10):1281-6
   PubMed Web of Science ®Google Scholar
• Huang GS, Juretzka M, Ciaravino G, Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma. Gynecol Oncol 2002;87(3):313-18
   PubMed Web of Science ®Google Scholar
• Caraglia M, Addeo R, Costanzo R, Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 2006;57(1):34-9
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Krown SE, Menell JH, Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003;21(17):3351-6
   PubMed Web of Science ®Google Scholar
• Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978;42(2):660-8
   PubMed Web of Science ®Google Scholar
• Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978;135(6):807-10
   PubMed Web of Science ®Google Scholar
• Hwu WJ, Lis E, Menell JH, Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005;103(12):2590-7
   PubMed Web of Science ®Google Scholar
• Krown SE, Niedzwiecki D, Hwu WJ, Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 2006;107(8):1883-90
   PubMed Web of Science ®Google Scholar
• Atkins MB, Sosman JA, Agarwala S, Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 2008;113(8):2139-45
   PubMed Web of Science ®Google Scholar
• Majer M, Jensen RL, Shrieve DC, Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer 2007;110(6):1329-37
   PubMed Web of Science ®Google Scholar
• Weber RW, O'Day S, Rose M, Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol 2005;23(35):8992-9000
   PubMed Web of Science ®Google Scholar
• Gogas H, Polyzos A, Stavrinidis I, Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2006;17(12):1835-41
   PubMed Web of Science ®Google Scholar
• Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem 2007;7:515-23
   PubMed Web of Science ®Google Scholar
• Plummer R, Jones C, Middleton M, Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008;14:7917-23
   PubMed Web of Science ®Google Scholar
• Horton TM, Jenkins G, Pati D, Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009;8(8):2232-42
   PubMed Web of Science ®Google Scholar
• Palma JP, Rodriguez LE, Bontcheva-Diaz VD, The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 2008;28(5A):2625-35
   PubMed Web of Science ®Google Scholar
• Besse B, Lasserre SF, Compton P, Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010;16(1):269-78
   PubMed Web of Science ®Google Scholar
• Zensi A, Begley D, Pontikis C, Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 2009;137(1):78-86
   PubMed Web of Science ®Google Scholar
• Katayama T, Shimizu J, Suda K, Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009;4(11):1415-19
   PubMed Web of Science ®Google Scholar
• Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 2009;65(2):198-203
   PubMed Web of Science ®Google Scholar
• Pan M, Santamaria M, Wollman DB. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. Nat Clin Pract Oncol 2007;4(10):603-7
   PubMedGoogle Scholar
• Koutras AK, Krikelis D, Alexandrou N, Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res 2007;27(6C):4255-7
   PubMed Web of Science ®Google Scholar
• Valcamonico F, Ferrari V, Amoroso V, Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol 2009;91(1):47-50
   PubMed Web of Science ®Google Scholar
• Murray A, Little SJ, Stanley P, Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy. Oncol Rep 2010;24(4):1049-58
   PubMed Web of Science ®Google Scholar